Last updated: May 25, 2026
CEFIDEROCOL SULFATE TOSYLATE Suppliers: Who Makes the API, Intermediates, and Drug Substance?
CEFIDEROCOL SULFATE TOSYLATE is a branded investigational antibacterial candidate (not a widely distributed commercial product in the US/EU supply chain). Public, regulator-linked supplier visibility (FDA Orange Book/NDC label manufacturers) is limited because the drug is not established as a marketed, fully commercialized product with standardized public sourcing footprints.
As a result, no complete, citation-grade supplier list for cefiderocol sulfate tosylate (API and drug substance) can be produced from the information available in the sources accessible within this workflow.
Which companies supply cefiderocol sulfate tosylate API and drug substance?
No verified supplier roster for cefiderocol sulfate tosylate API/drug substance can be provided.
Why supplier identification cannot be stated as fact
A credible supplier list requires at least one of the following, all of which are typically present for marketed products but are often absent for investigational candidates:
- FDA drug master file (DMF) holder names linked to the drug product and/or listed in NDA/ANDA-related records
- Orange Book listing with applicant/manufacturer identifiers tied to a specific NDA
- Public CGT/CTD sourcing disclosures in labeling or regulatory submissions
- Current GMP manufacturer listings in a publicly accessible regulatory package or product registration
None of those supplier-linkable artifacts are available in a way that supports a defensible, named-corporate answer for cefiderocol sulfate tosylate.
How do you identify cefiderocol sulfate tosylate suppliers via regulatory pathways (NDA, CTA, DMF)?
For investigational antibacterials like cefiderocol sulfate tosylate, the supplier chain is usually mapped through:
- DMF holders for the active pharmaceutical ingredient and key intermediates
- Contract manufacturing organizations (CMOs) used for sterile, tablet, or lyophilized dosage-form production
- Sponsor-managed manufacturing at development phase with later outsourcing once Phase III commences
A supplier list cannot be extracted as a set of named entities without the underlying regulatory filings or Orange Book/label-linked manufacturing statements.
What patent or exclusivity status affects cefiderocol sulfate tosylate manufacturing outsourcing?
Patent and exclusivity status can influence who is licensed to manufacture and whether API sourcing is constrained by process protection. However, without the specific US/EU marketing authorization record and its manufacturing/supplier disclosures, the supplier impact cannot be translated into a named supplier map.
What formulation and manufacturing steps drive supplier differentiation for cefiderocol sulfate tosylate?
Cefiderocol sulfate tosylate is typically associated with:
- Salt form management (sulfate with tosylate counterion association depending on the specific chemical description used in dossiers)
- Stability-driven crystallization and polymorph control
- Release testing tied to impurity profiles and residual solvent content
- Scale-up of an antibacterial core with tight impurity specifications
These factors determine which CMOs can qualify. A named supplier list still requires regulatory or label-linked data.
Key Takeaways
- A citation-grade, named supplier list for cefiderocol sulfate tosylate API/drug substance cannot be produced from available public regulatory supply-chain artifacts in this workflow.
- Cefiderocol sulfate tosylate supplier mapping normally depends on DMF/NDA/label-linked manufacturing disclosures, which are not present here in a supplier-identifiable form.
- Manufacturing eligibility is typically governed by salt form control, impurity specifications, and validated scale-up. Those determinants do not translate into actionable named suppliers without regulatory sourcing records.
FAQs
-
How can I find the DMF holder for cefiderocol sulfate tosylate?
DMF holder identification requires linking cefiderocol sulfate tosylate drug product submissions to DMFs in US regulatory records, which is not available in the current dataset.
-
Are there generic manufacturers for cefiderocol sulfate tosylate API?
No defensible public supplier roster can be stated; cefiderocol remains investigational with limited generalized API supplier visibility.
-
Do salt-form suppliers matter for cefiderocol sulfate tosylate?
Yes, salt form and crystallization control affect GMP eligibility and impurity profiles, but named salt-form suppliers cannot be verified here.
-
Which CMOs typically manufacture antibacterial IV drug substances and drug products like cefiderocol sulfate tosylate?
The identity of specific CMOs cannot be stated without regulatory or label-linked disclosures for cefiderocol sulfate tosylate.
-
Does cefiderocol sulfate tosylate have Orange Book listings that show manufacturers?
No supplier-linked Orange Book manufacturing entries can be used here to produce a list.
References
No sources were cited because no supplier-identifying regulatory artifacts were available to support named corporate claims.
